Effect of heterologous vaccination regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG antibodies titers

Romero-Ibarguengoitia, María Elena; Cantú, Arnulfo González; Hernández-Ruíz, Yodira Guadalupe; Amerndariz-Vázquez, Ana Gabriela; Rivera-Salinas, Diego; Montelongo-Cruz, Laura Patricia; Rio-Parra, Gerardo Francisco Del; Barco-Flores, Irene Antonieta; González-Facio, Rosalinda; Sanz-Sánchez, Miguel Ángel

doi:10.1101/2021.10.07.21264657

Cited by 3 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, the immune response wans. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] Antibody responses after third or booster dose vaccination among the general population [32,33,39,41,[43][44][45][47][48][49][50] and among immunocompromised patients have also been evaluated in multiple studies. The waning of immunity against different variants of SARS-CoV-2, such as Delta [16,19,22,25] and Omicron, [28,29] has been reported in several studies.…”

Section: Resultsmentioning

confidence: 99%

“…The search process identified 62 relevant studies: 17 were related to waning immunity, mostly after 6 months of vaccination [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] (Table 1 and Fig. 1), 19 papers were related to the third or booster dose vaccination (Table 2), [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] and 26 studies on the third or booster dose vaccination among immunocompromised patient populations (Table 3). Waning of immunity studies were among fully vaccinated, that is, 2 doses of vaccine, mostly the BNT162b2 mRNA vaccine, and the immune response was measured postvaccination.…”

Section: Resultsmentioning

confidence: 99%

“…No major SAEs were reported. [45] An open-label, nonran- (Malaysia) [46] Test [47] Prospective study among general population…”

Section: Yesmentioning

confidence: 99%

“…Several studies have been published that discussed the effects of SARS-CoV-2 vaccination boosters on human immunological responses. [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] However, the effect of new variants on vaccine effectiveness has not been well studied. Furthermore, the minimal level of neutralizing antibodies required to prevent infection or severe clinical consequences, as well as the relevance of vaccine-induced memory B and T cells against SARS-CoV-2, remains unknown.…”

Section: Sars-cov-2 Vaccine Doses: the Booster Appears To Improve Pro...mentioning

confidence: 99%

See 3 more Smart Citations

A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?

et al. 2022

View full text Add to dashboard Cite

Background: The emergence of new severe acute respiratory syndrome coronavirus 2 variants, along with the waning of vaccine-induced immunity, has increased breakthrough infections and urged booster jabs and debates. In the short term, the administration of booster doses has been reported to be safe and enhance severe acute respiratory syndrome coronavirus 2-specific neutralizing antibody levels. However, the effects of these doses on the pandemic trajectory and herd immunity are unclear. There is insufficient evidence that a third booster shot of the coronavirus disease 2019 (COVID-19) vaccine maintains longer immunity and covers new viral variants. The lack of sufficient evidence, combined with the fact that millions of people have not yet received 1 or 2 jabs of the COVID-19 vaccine, has raised concerns regarding the call for booster vaccinations.Methods: We conducted a quick scoping review to explore the literature on the need for a booster COVID-19 vaccination from January 1, 2021, to April 30, 2022.Results: Sixty-one relevant publications were identified, of which 17 were related to waning immunity after 2 doses of the vaccine among the general population or healthcare workers, 19 were related to the third or booster dose of vaccination after the second dose among the general population or healthcare workers, and 25 were related to booster dose among immunocompromised patient.Conclusions: Initially, the need for a booster dose was equivocal; however, several studies demonstrated the benefit of the booster dose over time. Adequate scientific information is required regarding the administration of booster doses to the general population as well as the high-risk individuals.Abbreviations: GMT = geometric mean titer, mRNA = messenger ribonucleic acid, NAb = neutralizing antibody, VOC = variants of concern.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…No major SAEs were reported. [45] An open-label, nonran- (Malaysia) [46] Test [47] Prospective study among general population…”

Section: Yesmentioning

confidence: 99%

Section: Sars-cov-2 Vaccine Doses: the Booster Appears To Improve Pro...mentioning

confidence: 99%

See 2 more Smart Citations

A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The first group was immunized with Ad5-nCoV vaccine, and the second group received a heterologous vaccination regimen containing Ad5-nCoV and BNT. Cases who received BNT as a boost after Ad5-nCoV showed higher SARS-CoV-2 spike 1–2 IgG antibody titers, without any severe adverse effect ( Romero-Ibarguengoitia et al, 2021 ). 14 trials in 6 countries assess safety and immunization of this vaccine and was approved in 10 countries.…”

Section: Viral Vector (Nonreplicating) Vaccine Candidatesmentioning

confidence: 99%

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Khoshnood

Ghanavati²,

Shirani³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

After about 2 years since the first detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Wuhan, China, in December 2019 that resulted in a worldwide pandemic, 6.2 million deaths have been recorded. As a result, there is an urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19). Endeavors for the production of effective vaccines inexhaustibly are continuing. At present according to the World Health Organization (WHO) COVID-19 vaccine tracker and landscape, 153 vaccine candidates are developing in the clinical phase all over the world. Some new and exciting platforms are nucleic acid-based vaccines such as Pfizer Biontech and Moderna vaccines consisting of a messenger RNA (mRNA) encoding a viral spike protein in host cells. Another novel vaccine platform is viral vector vaccine candidates that could be replicating or nonreplicating. These types of vaccines that have a harmless viral vector like adenovirus contain a genome encoding the spike protein of SARS-CoV-2, which induces significant immune responses. This technology of vaccine manufacturing has previously been used in many human clinical trials conducted for adenoviral vector-based vaccines against different infectious agents, including Ebola virus, Zika virus, HIV, and malaria. In this paper, we have a review of nucleic acid-based vaccines that are passing their phase 3 and 4 clinical trials and discuss their efficiency and adverse effects.

show abstract

Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

et al. 2022

View full text Add to dashboard Cite

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

show abstract

Effect of heterologous vaccination regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG antibodies titers

Cited by 3 publications

References 12 publications

A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?

A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

Contact Info

Product

Resources

About